Patent ID: 8044071
Filing Date: 2011-10-25
Classification: A61K,A61P

Abstract:
1. A method for treating a subject suffering from pain using a combination therapy comprising administering a selective CB 2 receptor agonist selected from the group consisting of (Z)—N-(5-tert-butyl-3-butylthiazol-2(3H)-ylidene)-5-chloro-2-methoxybenzamide and (Z)—N-(3-(2-methoxyethyl)-4,5-dimethylthiazol-2(3H)-ylidene)-2,2,3,3-tetramethylcyclopropanecarboxamide in an amount effective to obtain a therapeutic effect, and rimonabant in an amount effective to block any adverse effects mediated by the CB 1 receptor, but not to antagonize the therapeutic effect of the CB 2 receptor agonist.